Regulation of ovarian cancer stem cells or tumor-initiating cells.

Regulation of ovarian cancer stem cells or tumor-initiating cells.
复制标题

DOI:
10.3390/ijms14046624
复制
发表时间:
2013-03-25
影响因子:
5.6
通讯作者:
Shin YK
Shin YK
中科院分区:
生物学2区
文献类型:
--
作者:
Kwon MJ;Shin YK

文献摘要

参考文献

被引文献

相似文献

肿瘤干细胞或肿瘤起始细胞(CSC/TICS)可以自我更新和分化,在肿瘤的发生、耐药、肿瘤复发和转移中发挥重要作用。肿瘤复发和化疗耐药是卵巢癌患者生存率低的主要原因,部分原因可能与CSC/TICS的存在有关。因此,需要阐明卵巢CSC/TICS的分子机制,以开发治疗这种恶性肿瘤的方法。最近的研究表明,CSC/TICS的特性可以由microRNAs、基因和信号通路调节,这些信号通路也在正常干细胞中发挥作用。此外,新出现的证据表明,CSC/TICS周围的肿瘤微环境对这些细胞的维持至关重要。同样,目前正在努力解开卵巢CSC/TICS调控机制,尽管仍有许多工作要做。本文综述了近年来在识别参与卵巢CSC/TICs调控的基因和途径方面的进展。此外,还描述了目前针对卵巢CSC/TICS的治疗方法。靶向CSC/TICS和块状肿瘤细胞被认为是消除卵巢肿瘤的更有效的方法。更好地了解卵巢CSC/TICS的调控可能有助于改进复发卵巢癌的治疗策略。
Cancer stem cells or tumor-initiating cells (CSC/TICs), which can undergo self-renewal and differentiation, are thought to play critical roles in tumorigenesis, therapy resistance, tumor recurrence and metastasis. Tumor recurrence and chemoresistance are major causes of poor survival rates of ovarian cancer patients, which may be due in part to the existence of CSC/TICs. Therefore, elucidating the molecular mechanisms responsible for the ovarian CSC/TICs is required to develop a cure for this malignancy. Recent studies have indicated that the properties of CSC/TICs can be regulated by microRNAs, genes and signaling pathways which also function in normal stem cells. Moreover, emerging evidence suggests that the tumor microenvironments surrounding CSC/TICs are crucial for the maintenance of these cells. Similarly, efforts are now being made to unravel the mechanism involved in the regulation of ovarian CSC/TICs, although much work is still needed. This review considers recent advances in identifying the genes and pathways involved in the regulation of ovarian CSC/TICs. Furthermore, current approaches targeting ovarian CSC/TICs are described. Targeting both CSC/TICs and bulk tumor cells is suggested as a more effective approach to eliminating ovarian tumors. Better understanding of the regulation of ovarian CSC/TICs might facilitate the development of improved therapeutic strategies for recurrent ovarian cancer.
DOI: 10.1038/onc.2012.477
发表时间: 2013-09-19
期刊: ONCOGENE
影响因子: 8
作者:
Chapman-Rothe, N.;Curry, E.;Brown, R.
通讯作者: Brown, R.
DOI: 10.1042/bj20110112
发表时间: 2011-07-01
期刊: The Biochemical journal
影响因子: --
作者:
Barbolina MV;Burkhalter RJ;Stack MS
通讯作者: Stack MS
DOI: 10.1016/j.ygyno.2008.04.008
发表时间: 2008-08-01
影响因子: 4.7
作者:
Gotlieb, Walter H.;Saumet, Julio;Bruchim, Ilan
通讯作者: Bruchim, Ilan
DOI: 10.1371/journal.pone.0010277
发表时间: 2010-04-21
期刊: PloS one
影响因子: 3.7
作者:
Deng S;Yang X;Lassus H;Liang S;Kaur S;Ye Q;Li C;Wang LP;Roby KF;Orsulic S;Connolly DC;Zhang Y;Montone K;Bützow R;Coukos G;Zhang L
通讯作者: Zhang L
DOI: 10.4161/cc.23406
发表时间: 2013-02-01
期刊: CELL CYCLE
影响因子: 4.3
作者:
Chefetz, Ilana;Alvero, Ayesha B.;Mor, Gil
通讯作者: Mor, Gil